"Progression and Therapy" trang 1 - tải miễn phí từ tailieunhanh
Can advanced new radiation therapy technologies improve outcome of high grade glioma (HGG) patients? analysis of 3D-conformal radiotherapy (3DCRT) versus volumetric-modulated arc therapy (VMAT) in patients treated with surgery, concomitant and adjuvant chemoradiotherapy

Can advanced new radiation therapy technologies improve outcome of high grade glioma (HGG) patients? analysis of 3D-conformal radiotherapy (3DCRT) versus volumetric-modulated arc therapy (VMAT) in patients treated with surgery, concomitant and adjuvant chemoradiotherapy
10    52    1
A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy

A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy
11    88    1
Assessing the risk of rapid radiographic progression in Hungarian rheumatoid arthritis patients

Assessing the risk of rapid radiographic progression in Hungarian rheumatoid arthritis patients
9    29    1
High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer

High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
9    58    0
Post-progression treatment in cancer randomized trials: A cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020

Post-progression treatment in cancer randomized trials: A cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
10    4    1
Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
12    54    1
Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: A retrospective analysis

Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: A retrospective analysis
13    81    0
Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: A prospective, phase II, multicentre, single-arm study

Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: A prospective, phase II, multicentre, single-arm study
7    80    0
Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer

Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer
5    83    1
DocOx (AIO-PK0106): A phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma

DocOx (AIO-PK0106): A phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma
9    66    1
Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy

Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy
9    65    1
Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma

Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma
8    45    1
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic nonsmall cell lung cancer TRAP OLIGO study (WJOG11118L)

Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic nonsmall cell lung cancer TRAP OLIGO study (WJOG11118L)
6    38    1
Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: A retrospective analysis

Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: A retrospective analysis
7    18    1
The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma

The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma
10    1    1
Silent progression in patients with rheumatoid arthritis: Is DAS28 remission an insufficient goal in RA? Results from the German Remission-plus cohort

Silent progression in patients with rheumatoid arthritis: Is DAS28 remission an insufficient goal in RA? Results from the German Remission-plus cohort
9    27    1
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
10    5    1
INSURANCE YEAR IN REVIEW 2011

INSURANCE YEAR IN REVIEW 2011
60    92    0
Income Support Policies and Health among the Elderly 

Income Support Policies and Health among the Elderly 
38    90    0
REDUCING ENVIRONMENTAL CANCER RISK

REDUCING ENVIRONMENTAL CANCER RISK
240    107    0